CellChorus
YC S21Houston, US · Founded 2020 · 4 employees · 2 known investors
CellChorus develops a visual AI platform called TIMING that performs high-throughput dynamic analysis of single cells, measuring cell activation, killing, and movement over time for biopharmaceutical research. The company serves biopharmaceutical companies and therapy developers seeking to understand cellular function and phenotype.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesAI-powered Drug DiscoveryMachine Learningin /cellchorus@CellChorus
Founders & leadership· Y Combinator alumni (S21)
Investors · 2
In the news
- CellChorus, Stanford Medicine land National Cancer Institute SBIR grant - InnovationMaphouston.innovationmap.com · 2026
- NCI Award CellChorus and Stanford Medicine SBIR award — CellChoruscellchorus.com · 2026
- BioTools Innovator VANGUARD awards CellChorus contract to support AI-enabled pathogen-immune profiling - MedTech Innovatormedtechinnovator.org · 2025
- BioTools Innovator VANGUARD awards CellChorus contract to support pathogen-immune profilingcellchorus.com · 2025
- Four abstracts at SITC 2024 to feature CellChorus TIMING datacellchorus.com · 2024
- Cancer Discovery publication applies TIMING to show increased serial killing by novel CAR NK therapy — CellChoruscellchorus.com · 2024
- University of Houston-founded company secures $2.5M in NIH grant funding - InnovationMaphouston.innovationmap.com · 2024
- Up to $2.5 million in funding from NIH will be used to develop TIMING™ kits for manufacturing analytics that provide end-users with rapid, specific and predictive results to accelerate translational research and the development and manufacture of more effective cell therapies to benefit patients - Mmedtechinnovator.org · 2024